君实生物(01877.HK) (688180.SH) 公布，其控股子公司上海旺实生物医药科技收到国家药监局核准签发的《药品补充申请批准通知书》，氢溴酸氘瑞米德韦片(商品名：民得维，产品代号：VV116/JT001)用于治疗轻中度新型冠状病毒(COVID-19)感染的成年患者的适应症获得国家药监局同意，由附条件批准转为常规批准。
研究结果显示，在轻、中度COVID-19患者中，民得维可显著加速症状缓解和消失、缩短病程，加快病毒转阴，降低重症COVID-19或全因死亡发生率，对老年和高风险患者效果更显著。在轻中度肝肾功能不全的患者中，民得维表现出良好的安全性和耐受性，患者在服药过程中无需或仅需少量调整用药剂量。同时，药理研究显示民得维基本无药物间相互作用，大大减少用药禁忌，有效保障患者的合并用药，为特殊人群提供更安全、更有效的选择。(jl/w)(港股报价延迟最少十五分钟。沽空资料截至 2025-01-10 16:25。) (A股报价延迟最少十五分钟。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.